Your browser doesn't support javascript.
loading
Discordance between peritumoral and subareolar injections for mapping sentinel lymph nodes in the breast.
Situ, Josephine; Walker, Cameron; Jayathungage Don, Tharanga D; Suami, Hiroo; Chung, David K V; Reynolds, Hayley M.
Afiliación
  • Situ J; Department of Engineering Science, The University of Auckland, Auckland, New Zealand.
  • Walker C; Department of Engineering Science, The University of Auckland, Auckland, New Zealand.
  • Jayathungage Don TD; Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand.
  • Suami H; Australian Lymphoedema Education Research and Treatment Program (ALERT), Department of Health Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
  • Chung DKV; Alfred Nuclear Medicine and Ultrasound, Newtown, NSW, Australia.
  • Reynolds HM; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Breast Cancer Res Treat ; 2024 Sep 15.
Article en En | MEDLINE | ID: mdl-39277550
ABSTRACT

PURPOSE:

Sentinel node biopsy (SNB) is a common staging tool for breast cancer. Initially, peritumoral (PT) injections were used, however subareolar (SA) injections were later introduced to simplify the technique. Controversy remains regarding whether PT and SA injections map the same sentinel lymph nodes (SLNs). This study aimed to determine whether the regional location of breast SLNs differs when using PT versus SA injections using a large dataset from a single institution.

METHODS:

A total of 1035 patients who underwent breast SNB (PT injections n = 858 and SA injections n = 177) with lymphoscintigraphy and SPECT/CT were included. The identified SLN locations using SA injections were compared with those using PT injections. Differences in drainage proportions and odds ratios (ORs) for each clockface breast region and the whole breast were calculated using a two-proportion z-test and Fisher's Exact Test.

RESULTS:

A higher proportion of internal mammary SLNs were identified using PT injections for the whole breast (0.30 versus 0.09) and for all breast regions, with all regions showing statistical significance except the upper outer quadrant. Similarly, ORs showed identification of internal mammary SLNs was significantly higher when using PT injections (4.35, 95% CI 2.53 to 7.95). There were no significant differences in identifying axillary SLNs between injection sites.

CONCLUSION:

This is the largest cohort study to compare the regional location of breast SLNs identified using PT injections versus SA injections. Discordance was shown in the SLNs identified between injection techniques, with PT injections more frequently identifying internal mammary SLNs.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Breast Cancer Res Treat Año: 2024 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Países Bajos